AG-858 in Patients Who Are Cytogenetically Positive After Treatment With Gleevec™
Status:
Terminated
Trial end date:
2006-04-01
Target enrollment:
Participant gender:
Summary
This is a Phase II, exploratory, open-label study of the investigational product AG-858, in
patients who are cytogenetically positive after treatment with Gleevec.
The trial will consist of three independent Phase II evaluations of patient groups according
to their cytogenetic status as defined in the eligibility criteria (Eligibility Criteria 4a,
4b, and 4c).